Janus Henderson Investors — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+6 more
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)WINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)
BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in
Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupSection 32+3 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritvenBio PartnersREDMILESamsara BioCapitalvenBio Global Strategic+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.